Abstract
Kv1.2 and Kv1.5 are two subtypes of voltage-gated potassium channels expressed in heart that are thought to contribute to phase 1 (ITO) and phase 3 (IK) components of cardiac action potential repolarization. Although the effect of decreased pH in prolonging cardiac action potentials is well documented, the molecular target of acidification has not previously been determined. We expressed Kv1.2 and Kv1.5 in Xenopusoocytes to study the effect of acidic and alkaline extracellular pH on channel function. Using two-electrode voltage clamp and cellattached patch clamp, we demonstrate that Kv1.5 channels show enhanced C-type inactivation at acidic pH that is relevant to pathophysiological conditions. In contrast, homologous Kv1.2 channels are resistant to acidic pH. Both channel types are insensitive to alkaline pH. A histidine residue in the third extracellular loop of Kv1.5 (H452) accounts for the difference in pH sensitivity between the Kv1.5 and Kv1.2 channels. Mutation of histidine H452 to a glutamine residue in Kv1.5 yields a channel that no longer shows enhanced inactivation with acidification. These data provide insight into mechanisms subserving known pH effects on cellular signaling functions. Our results demonstrate that H452 in the third extracellular loop of Kv1.5 plays a role in C-type inactivation, thus expanding the known complement of protein regions that contribute to the slow K+ channel inactivation mechanism.
Footnotes
-
Send reprint requests to: Dr. Andrea J. Yool, Ph.D., Department of Physiology, University of Arizona, College of Medicine, Tucson AZ 85724-5051. E-mail ayool{at}u.arizona.edu
-
This study was supported by grants from the National American Heart Association (AHA 96007620), the American Heart Association, Southwest Affiliate (AHA SWA-FWP-10-98), and the National Institutes of Health (NIH HL07249–19). This work was previously presented in abstract form at the 28th Annual Meeting of the Society for Neuroscience, Los Angeles California, November 1998.
- Abbreviations:
- bpm
- beats per minute
- Received December 29, 1998.
- Accepted February 14, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|